AngioDynamics Will Break Into Oncology Biz With $220 Mil. Rita Purchase
This article was originally published in The Gray Sheet
Executive Summary
AngioDynamics will gain immediate access to the targeted tumor ablation market and will fill out its vascular access business in a $220 mil. acquisition of Rita Medical
You may also be interested in...
The Evolving World Of Breast Cancer Management
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.
AngioDynamics/Rita
AngioDynamics subsidiary Rita Medical pays $2,750 to the U.S. government to settle allegations that it traded with an entity in Iran between October 2002 and January 2003 without disclosing the activities to the Treasury Department's Office of Foreign Assets Control, a violation of the Iranian Transactions Regulations. AngioDynamics bought radiofrequency ablation device maker Rita for $220 million in January (1"The Gray Sheet" Dec. 4, 2006, p. 10). Another device maker, EP MedSystems, paid $277,000 to settle similar charges in 2006 and earlier this year
AngioDynamics/Rita
AngioDynamics subsidiary Rita Medical pays $2,750 to the U.S. government to settle allegations that it traded with an entity in Iran between October 2002 and January 2003 without disclosing the activities to the Treasury Department's Office of Foreign Assets Control, a violation of the Iranian Transactions Regulations. AngioDynamics bought radiofrequency ablation device maker Rita for $220 million in January (1"The Gray Sheet" Dec. 4, 2006, p. 10). Another device maker, EP MedSystems, paid $277,000 to settle similar charges in 2006 and earlier this year